NEW YORK (GenomeWeb News) — Shares in Gene Logic were down 15.47 percent, or $.30, at $1.64 in midday trading after the company this morning said third-quarter revenue slid 39 percent, and that it plans to sell its preclinical services division.
 
After stating in September that the preclinical services segment would not be put on the block, today Gene Logic said it has hired an investment firm to help it divest the unit, and is currently in discussions for the sale.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.